International Companies

Novo Nordisk trial results fall short, shares tumble

By Abigail Townsend

Date: Monday 23 Feb 2026

(Sharecast News) - Shares in Novo Nordisk plunged on Monday, after a trial for a new weight-loss treatment failed to meet its end target.
The Danish owner of obesity and diabetes drugs Ozempic and Wegovy said novel treatment CagriSema - a once-weekly injection combining two molecules - achieved 23% weight loss...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page